Free Trial
→ Analyst nicknamed “The Prophet” issues new warning for America (From Stansberry Research) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$156.50
-0.3%		$162.94
$153.41
▼
$212.71
$243.34B0.272.88 million shs2.26 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$23.30
-1.4%		$26.81
$22.30
▼
$47.65
$2.09B0.691.48 million shs1.08 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-0.26%-5.77%-3.76%-18.81%-8.28%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-1.40%-9.09%-17.41%-23.51%-38.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Astrazeneca Plc stock logo
AZN
Astrazeneca
$156.50
-0.3%		$162.94
$153.41
▼
$212.71
$243.34B0.272.88 million shs2.26 million shs
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
$23.30
-1.4%		$26.81
$22.30
▼
$47.65
$2.09B0.691.48 million shs1.08 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Astrazeneca Plc stock logo
AZN
Astrazeneca
-0.26%-5.77%-3.76%-18.81%-8.28%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-1.40%-9.09%-17.41%-23.51%-38.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Astrazeneca Plc stock logo
AZN
Astrazeneca
2.72
Moderate Buy$206.6732.05% Upside
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
2.50
Moderate Buy$48.80109.44% Upside

Current Analyst Ratings Breakdown

Latest AZN and MLYS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/15/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Deutsche Bank Aktiengesellschaft logo
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell ➝ Hold
9/14/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
9/11/2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
9/8/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform
8/23/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
CICC Research logo
CICC Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform$198.00
8/13/2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold ➝ Strong Sell
7/28/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
7/17/2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/13/2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy ➝ Hold
(Data available from 10/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Astrazeneca Plc stock logo
AZN
Astrazeneca
$58.74B4.13$12.89 per share12.14$31.41 per share4.98
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/A$8.17 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Astrazeneca Plc stock logo
AZN
Astrazeneca
$10.23B$6.6923.3914.831.3217.02%31.45%13.20%10/30/2026 (Estimated)
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$154.65M-$4.24N/AN/AN/AN/A-57.97%-54.15%11/9/2026 (Estimated)

Latest AZN and MLYS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
10/30/2026Q3 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.62N/AN/AN/A$16.06 billionN/A
8/12/2026Q2 2026
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
-$0.5486-$2.85-$2.3014-$2.85N/AN/A
7/27/2026Q2 2026
Astrazeneca Plc stock logo
AZN
Astrazeneca
$2.50$2.63+$0.13$1.61$15.44 billion$15.38 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Astrazeneca Plc stock logo
AZN
Astrazeneca
$4.342.77%+2.30%64.87%N/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Astrazeneca Plc stock logo
AZN
Astrazeneca
0.47
0.89
0.67
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
0.18
34.46
34.46

Institutional Ownership

CompanyInstitutional Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
20.35%
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
84.46%

Insider Ownership

CompanyInsider Ownership
Astrazeneca Plc stock logo
AZN
Astrazeneca
N/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
18.94%
CompanyEmployeesShares OutstandingFree FloatOptionable
Astrazeneca Plc stock logo
AZN
Astrazeneca
96,1001.55 billionN/AN/A
Mineralys Therapeutics, Inc. stock logo
MLYS
Mineralys Therapeutics
7688.41 million71.66 millionOptionable

Recent News About These Companies

Mineralys Grants Equity Awards to New Employees
October 5 at 3:23 PM  |  mychesco.comM
Mineralys (NASDAQ: MLYS) CEO sells 75,000 shares under prearranged plan
October 5 at 2:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31085619
Mineralys Therapeutics (NASDAQ:MLYS) CEO Jon Congleton Sells 75,000 Shares of Stock
October 3 at 5:23 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31082814
Mineralys Therapeutics (NASDAQ:MLYS) Stock: Insider Jon Congleton Sells 75,000 Shares
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-mineralys-therapeutics-nasdaq-mlys-stock-insider-jon-congleton-sells-75000-shares-2026-10-02/
Mineralys Therapeutics Announces Launch-HTN Data Presentation on Lorundrostat at ASN Kidney Week 2026
October 2, 2026  |  quiverquant.comQ
Mineralys Therapeutics Announces Presentation of New Lorundrostat Data at the American Society of Nephrology (ASN) Kidney Week 2026
October 2, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/02/3374037/0/en/mineralys-therapeutics-announces-presentation-of-new-lorundrostat-data-at-the-american-society-of-nephrology-asn-kidney-week-2026.html
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Receives Consensus Recommendation of "Moderate Buy" from Analysts
October 2, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31077856
Mineralys Therapeutics, Inc. (NASDAQ:MLYS) Stock Rated "Moderate Buy" by Sell-Side Analysts
October 2, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-mineralys-therapeutics-inc-nasdaq-mlys-stock-rated-moderate-buy-by-sell-side-analysts-2026-10-02/
Mineralys Therapeutics Announces Presentation of Lorundrostat Data at American Heart Association Hypertension Scientific Sessions 2026
October 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/01/3373386/0/en/mineralys-therapeutics-announces-presentation-of-lorundrostat-data-at-american-heart-association-hypertension-scientific-sessions-2026.html
Mineralys Therapeutics (NASDAQ:MLYS) Stock Falls 6.1% - What's Next?
October 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-mineralys-therapeutics-nasdaq-mlys-stock-falls-61-whats-next-2026-10-01/
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - September 29, 2026
September 29, 2026  |  biospace.comB
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
September 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/29/3371318/0/en/mineralys-therapeutics-reports-inducement-awards-under-nasdaq-listing-rule-5635-c-4.html
Mineralys Therapeutics (MLYS) Faces A Fresh Valuation Test On New Lorundrostat Data
September 28, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/mineralys-therapeutics-mlys-faces-fresh-170811964.html
Insider Selling: Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 104,320 Shares of Company Stock
September 26, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-mlys-insider-buying-and-selling-2026-09-26/
Mineralys Therapeutics (NASDAQ:MLYS) Director Sells 104,320 Shares of Stock
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31048257
Mineralys Therapeutics (NASDAQ:MLYS) Director Brian Taylor Slingsby Sells 104,320 Shares of Company Stock
September 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-mineralys-therapeutics-nasdaq-mlys-director-brian-taylor-slingsby-sells-104320-shares-of-company-stock-2026-09-25/
Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 8.1% on Insider Selling
September 25, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31046923
Mineralys Therapeutics, Inc. Announces Transform-HTN Open-Label Extension Trial Data Selected For Late-Breaking Presentation At American Heart Association Scientific Sessions 2026
September 24, 2026  |  marketscreener.comM
Mineralys Therapeutics’ Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
September 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/mineralys-therapeutics-transform-htn-open-label-extension-trial-data-selected-for-late-breaking-presentation-at-american-heart-association-scientific-sessions-2026-1036569060
Mineralys Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368738/0/en/mineralys-therapeutics-to-participate-in-the-stifel-2026-virtual-cardiometabolic-forum.html
Mineralys Therapeutics' Transform-HTN Open-Label Extension Trial Data Selected for Late-Breaking Presentation at American Heart Association Scientific Sessions 2026
September 23, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/23/3367839/0/en/mineralys-therapeutics-transform-htn-open-label-extension-trial-data-selected-for-late-breaking-presentation-at-american-heart-association-scientific-sessions-2026.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Astrazeneca stock logo

Astrazeneca NYSE:AZN

$156.50 -0.40 (-0.25%)
Closing price 10/5/2026 03:59 PM Eastern
Extended Trading
$159.50 +3.00 (+1.92%)
As of 10/5/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Mineralys Therapeutics stock logo

Mineralys Therapeutics NASDAQ:MLYS

$23.30 -0.33 (-1.40%)
Closing price 10/5/2026 04:00 PM Eastern
Extended Trading
$23.30 +0.00 (+0.02%)
As of 10/5/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas